LGND ▼ -0.0% - Ligand Pharmaceuticals Incorporated $LGND - Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million Ligand Pharmaceuticals acquired a royalty and milestone interest in Santen's Ryjunea®, a dry eye disease treatment, from Sydnexis for $23 million, positioning the company to receive ongoing payments as the drug generates sales. The transaction had no material impact on the stock, which closed essentially flat. 22-SEP-2026 07:00 AM ET